68 results about "Cytokine release syndrome" patented technology

The invention relates to specific chimeric antigen receptor T cells targeting CD19, and a preparation method and clinical application thereof. The present invention constructs a specific chimeric antigen receptor targeting CD19 and immune response cells modified by the chimeric antigen receptor based on a targeted human CD19 single-chain antibody sequence. The novel modified immune response cells can effectively target and attack a plurality of tumor cells, especially tumor cells with positive CD19 expressiion, and can be used to prepare a preparation for the treatment of tumors. The method for preparing the modified immune response cells targeting CD19 is simple, and the obtained modified immune response cells targeting CD19 have a high killing rate on tumor cells. Clinical verification shows that: after a million-grade low-dose back transfusion, patients with recurrent and refractory advanced CD19-positive lymphoma get a significant clinical symptom relief after two weeks of treatment, almost complete relief curative effect is obtained on the 77th day, and no fever caused by cytokine release syndrome and any neurotoxic side effect occur.

The present disclosure provides method of preventing, lessening the effects, or treating cytokine release syndrome (CRS) or related disorders, and/or neurotoxicity associated with immunotherapy comprising administering defibrotide. The defibrotide can be administered after the immunotherapy begins or be administered prophylactically before immunotherapy begins or before the patient develops CRS and/or neurotoxicity.

The invention is directed to a method of determining whether an agent causes immune toxicity in a human comprising administering the agent to a non-human mammal that has been engrafted with human hematopoietic stem cells (HSCs) and administered one or more human cytokines; and determining whether the agent causes immune toxicity in the non-human mammal. If the agent causes immune toxicity in the non-human mammal then the agent causes toxicity in a human. The invention is also directed to a method of determining whether administration of an agent causes cytokine release syndrome in an individual in need thereof comprising administering the agent to a non-human mammal that has been engrafted with HSCs and administered one or more human cytokines; and determining whether the agent causes cytokine release syndrome in the non-human mammal. If the agent causes cytokine release syndrome in the non-human mammal then the agent will cause cytokine release syndrome in the human.

The present invention relates to a formulation comprising an inhibitor of NFAT activation for use in treating or preventing undesirable effects, more particularly undesirable effects occurring in conjunction with T cell-mediated therapies. The undesirable effects may be cytokine release syndrome (CRS) or symptoms associated with gastrointestinal (GI) inflammation, for example associated with inflammatory bowel diseases, such as ulcerative colitis, optionally caused by activated T cell activity. In addition to ameliorating undesirable effects, the invention is aimed at also maintaining the therapeutic effects of the T-cell mediated therapy.

The present disclosure is directed to a composition comprising micronized cromolyn sodium, α-lactose, and a salt of fatty acid, wherein the α-lactose has a particle size distribution of D₉₀ of 45-70 μm, D₅₀ of 10-35 μm, and D₁₀ of 2-13 μm. The present disclosure is also directed to a method of treating Alzheimer's disease, amyloidosis-associated condition (AAC), traumatic brain injury, Huntington's disease, atherosclerosis, cytokine release syndrome (CRS), dementia, head injury, infection, neuroinflammation, prion disease, stroke, amyotrophic lateral sclerosis (ALS), Parkinson's disease, or asthma using the composition.

Compositions and methods for treating a cytokine release syndrome such as chimeric antigen receptor T-cell cytokine release syndrome or hemophagocytic lymphohistiocytosis are provided.

The invention discloses an application of a CDK7 targeting inhibitor in preparation of a medicine for treating cytokine release syndrome, which is verified by biochemical and animal model experiments as follows: (1) under proper concentration, the CDK7 targeting inhibitor inhibits the expression of super enhancers and transcription factors related to inflammatory factors such as stat1, IL-1 and IL-6, and thereby inflammatory signal pathways of immune cells such as macrophages, T cells and endothelial cells can be specifically regulated and controlled; (2) mouse death caused by acute inflammatory storm caused by bacterial or viral infection can be remarkably reduced, functional failure caused by inflammation of related organs is reduced, and obvious toxic and side effects are not found in the period. According to the results, the polypeptide has great significance in treatment of cytokine release syndrome caused by bacteria, viruses or immunotherapy.

The invention belongs to the technical field of biology, and particularly relates to an in-vitro cytokine storm model and a construction method and application thereof. The construction system of the in-vitro cytokine storm model contains a TNF-alpha factor, an IL-1[beta] factor, an IL-6 factor and vascular endothelial cells. The in-vitro cytokine storm model is formed by the body. According to the in-vitro cytokine storm model construction method, vascular endothelial cells, TNF-alpha factors, IL-1[beta] factors and IL-6 factors are incubated together. The invention discloses application of an in-vitro cytokine storm model in screening of anti-cytokine release syndrome drugs. The invention relates to an application of an in-vitro cytokine storm model in preparing and screening anti-cytokine release syndrome drugs. The in-vitro cytokine storm model disclosed by the invention is obtained by jointly treating vascular endothelial cells through three factors, namely TNF-alpha, IL-1[beta] and IL-6, the in-vitro cytokine storm model with high cell apoptosis rate and obviously reduced cell activity can be prepared, and a better basis is provided for research on inflammatory response related to multiple factors.

The invention discloses two shRNAs (short hairpin RNA) interfering with human IFN (interferon)-gama gene expression shown as SEQ ID NO: 1 and SEQ ID NO: 2. The invention further discloses a lentiviralexpression vector. The lentiviral expression vector contains the shRNAs interfering with the human IFN-gama gene expression and a chimeric antigen receptor encoding nucleotide fragment shown as SEQ ID NO: 4. The invention further discloses a CD19-CAR-T cell interfering with the human IFN-gama gene expression. The CD19-CAR-T cell is a T lymphocyte containing the lentiviral expression vector, or aT lymphocyte which is integrated with the shRNAs interfering with the human IFN-gama gene expression and the chimeric antigen receptor encoding nucleotide fragment in a chromosome. The IFN-gama shRNAsare introduced into the CAR-T cell, the shRNAs of IFN-gama are coexpressed while CAR is expressed, and release of the IFN-gama is inhibited from the source by a gene silencing technology, so that influence of CRS (cytokine release syndrome) is reduced and the safety of CAR-T treatment is improved. Important application to preparation of medicines for prevention, treatment and adjuvant treatment of malignant tumors can be expected.

The invention discloses siRNA for knocking down human IL-15, a CD19 CAR expression vector, a CD19 CAR-T cell and application of siRNA based on the problem that IL-15 released by the CD19 CAR-T cell through self-activating proliferation cannot be controlled by a method, relating to the technical field of tumor immunotherapy. The invention discloses siRNA for knocking down human IL-15, a lentiviralexpression vector of siRNA and the CD19 CAR-T cell for knocking down IL-15. The siRNA has the beneficial effects that the knock-down effect of IL-15 in the CD19 CAR-T cell is realized, and the secretion volume of IL-15 is greatly reduced, so that the risks of cell factor release syndrome and encephaledema are reduced.

The invention discloses construction and application of a fourth-generation chimeric antigen receptor (CAR)-T cell secreting anti-GM-CSF scFv for neutralizing GM-CSF and having GM-CSF gene knockdown.The integral safety of CAR-T therapy can be improved by secreting anti-GM-CSF scFv neutralizing the GM-CSF, combining the GM-CSF gene knockdown in the CAR-T cell, preventing or retarding occurrence and development of the cytokine release syndrome and the neurotoxicity. Furthermore, a nucleotide sequence encoding microRNA is inserted into an EF1 alpha promoter, and the package titer of a chronic virus carrier is not influenced.

The present disclosure relates to a method of treating at least one Cell-Associated Neurotoxicity Syndrome (ICANS), cancer-related cognitive impairment, Infusion Reaction Syndrome (IRS), Capillary Leak Syndrome (CLS), Tumor Lysis Syndrome (TLS), Macrophage Activation Syndrome (MAS), Systemic Inflammatory Response Syndrome (SIRS), Immune Reconstitution Inflammatory Syndrome (IRIS), Graft-Versus-Host Disease (GVHD), Acute Respiratory Distress Syndrome (ARDS), sepsis, Ebola, avian influenza, smallpox, Systemic Inflammatory Response Syndrome (SIRS), and Immune-related Adverse Events Syndrome (IrAES) in a subject in need thereof, comprising administering a mast cell stabilizer or a compound of Formula I or Formula II: Formula I, Formula II, wherein R¹ is halogen, OH, or —OC(O)C_1-5alkyl R² and R³ are each independently selected from CO₂R⁴ or CH²OR⁵; R⁴ is i L, Na, K, H, C_1-5alkyl, or —CH₂CO(C_1-5alkyl); and R⁵ is H or C(O)(C_1-5alkyl), or a pharmaceutically acceptable salt thereof.

Methods of using Metrnl/IL-41 to identify inflammation, inflammatory and autoimmune diseases, infection and cancer in a subject are provided. The methods include determining the serum or plasma levels of Metrnl/IL-41 in the subject. Methods of modulating a condition selected from cytokine release syndrome, systemic immune response syndrome, cytokine storm, or a combination thereof, using Metrnl/IL-41 or antibodies against Metrnl/I-41 are also provided.